

Impact and cost-effectiveness of doxycycline post-exposure prophylaxis for sexually transmitted infections in Australian men who have sex with men



ACCEPTANCE CODE
EE66

Hao Lai^{1,2} Jason J. Ong^{3,4} Michael W. Traeger^{5,6,7} Christopher K. Fairley^{3,4} Benjamin P. Howden⁸ Mark A. Stoové^{5,6,9} Mingwang Shen^{1,10,11,12,*} Lei Zhang^{1,2,3,4,*}

1. China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, PR China; 2. Phase I clinical trial research ward, The Second Affiliated Hospital of Xi'an Jiaotong University, No.157 Xi Wu Road, Xi'an 710004, Shaanxi Province, PRC; 3. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia; 4. School of Translational Medicine, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, Australia; 5. Burnet Institute, Melbourne, VIC, Australia; 6. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; 7. Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, United States; 8. Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; 9. School of Psychology and Public Health, La Trobe University, Melbourne, Australia; 10. Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an, Shaanxi, 710061, PR China; 11. The Interdisciplinary Center for Mathematics and Life Sciences, School of Mathematics and Statistics, Xi'an Jiaotong University, Xi'an, Shaanxi, 710049, PR China; 12. Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, Xi'an, Shaanxi, 710061, PR China.

① Background & Objective

The optimal implementation of doxy-PEP in Australian GBMSM remains uncertain because broader eligibility may increase antimicrobial resistance and alter cost-effectiveness.

Objective: compare five targeted strategies with no doxy-PEP over 2025–2034 across epidemiological, resistance and economic outcomes.

② Model & Strategies


- Individual-based stochastic network model of gonorrhoea, chlamydia and syphilis.
- Calibrated to national data (900 independent simulations)
- 75% uptake · 80% adherence · within 72 hours · 6-month prescription.

Five targeting strategies

1. One syphilis diagnosis
2. Two STI diagnoses in 6 months
3. Two STI diagnoses in 12 months
4. HIV-positive attendees
5. PrEP-using attendees

③ Antimicrobial Resistance

HL TetR (proxy for doxycycline resistance) rose under every strategy; syphilis targeting added the fewest resistant infections (+955 vs +3,412 PrEP-wide).



④ Economic Findings

All five strategies were cost-saving.

The syphilis strategy had the highest BCR: 9.2 (95% UI 7.1–11.3).

Infections averted per prescription: 7.6 for syphilis targeting versus 2.1 for PrEP-wide eligibility.

⑤ Decision Trade-off

Syphilis-targeted

16.4% fewer STIs, +955 HL TetR infections, BCR 9.2


PrEP-using attendees

47.8% fewer STIs, +3,412 HL TetR infections, BCR 1.9
Interpretation: broader eligibility maximized infections averted, but reduced efficiency and increased the resistance burden.


Conclusion

Targeting GBMSM after a syphilis diagnosis provided the strongest overall balance of STI prevention, antimicrobial resistance and economic value. It reduced overall STIs by 16.4%, had the highest BCR (9.2), and ranked first in 9 of 11 policy frameworks.


Incidence | STIs fell, tetracycline-resistant gonorrhoea rose



Cumulative Impact | 2025–2034 · 95% UI · n = 900



Benefit-Cost Ratios | All strategies were cost-saving



Multi-criteria Ranking | Eleven policy frameworks

